Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
Carcinoma, Non-Small-Cell Lung|ErbB Receptors
DRUG: Afatinib
Percentage of Patients With Occurrence of Adverse Events (AEs) Leading to Dose Reduction of Afatinib, Percentage of patients with occurrence of Adverse Events (AEs) leading to dose reduction of afatinib., Up to 98 days
Percentage of Patients With Occurrence of CTCAE Grade 3 or Higher Diarrhoea, Rash/Acne+, Stomatitis+ and Paronychia+ (+ Represents Grouped Term), Percentage of patients with occurrence of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher diarrhoea, rash/acne+, stomatitis+ and paronychia+ (+ represents grouped term)., Up to 98 days|Time to First Dose Reduction of Afatinib Caused by Adverse Events (AEs), Time to first dose reduction of afatinib caused by Adverse Events (AEs) defined as time from the date of the first administration of afatinib to the first dose reduction of afatinib caused by AEs., Up to 98 days
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.